Idiopathic Pulmonary Fibrosis (IPF) is a deadly interstitial lung disease. Short of lung transplantation there is no proven effective treatment for the disease process. The disease is characterized by progressive scarring of the airspaces. The primary cell type responsible for the progressive scarring is the lung fibroblast. Recent work suggests that the lung fibroblast in IPF has distinct pathological properties enabling it to abnormally proliferate and survive. However, large gaps in knowledge remain regarding differences between the pathological nature of fibroblasts in IPF responsible for progressive proliferation and the limited physiological proliferation of normal fibroblasts necessary for prope lung repair. In preliminary studies, we have discovered pathological alterations in key signaling pathways that regulate IPF fibroblast proliferation and survival. This proposal seeks to further characterize key differences between normal and IPF fibroblasts that underline the aberrant ability of IPF fibroblasts to proliferate and scar airspaces. These experiments could suggest new therapeutic strategies for this lethal disease.

Public Health Relevance

Idiopathic Pulmonary Fibrosis (IPF) is a lethal lung disease and currently there is no effective medical therapy available to cure or prevent this disease. In this study, we have found that crucial signaling molecules are abnormally altered in IPF fibroblasts and in lung specimens with IPF. Thus the elucidation of pathological mechanisms in IPF fibroblasts greatly helps design a therapeutic target to limit the progression of IPF.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Eu, Jerry Pc
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Yhee, Ji Young; Yoon, Hong Yeol; Kim, Hyunjoon et al. (2017) The effects of collagen-rich extracellular matrix on the intracellular delivery of glycol chitosan nanoparticles in human lung fibroblasts. Int J Nanomedicine 12:6089-6105
Im, Jintaek; Kim, Kyutae; Yhee, Ji Young et al. (2016) Desensitization of idiopathic pulmonary fibrosis fibroblasts to Alternaria alternata extract-mediated necrotic cell death. Physiol Rep 4:
Im, Jintaek; Kim, Kyutae; Hergert, Polla et al. (2016) Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3. J Pathol 240:25-37
Yhee, Ji Young; Im, Jintaek; Nho, Richard Seonghun (2016) Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery. J Clin Med 5:
Park, Ji-Man; Jung, Chang Hwa; Seo, Minchul et al. (2016) The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14. Autophagy 12:547-64
Im, Jintaek; Hergert, Polla; Nho, Richard Seonghun (2015) Reduced FoxO3a expression causes low autophagy in idiopathic pulmonary fibrosis fibroblasts on collagen matrices. Am J Physiol Lung Cell Mol Physiol 309:L552-61
Nho, Richard Seonghun (2015) Alteration of Aging-Dependent MicroRNAs in Idiopathic Pulmonary Fibrosis. Drug Dev Res 76:343-53
Nho, Richard Seonghun; Hergert, Polla (2014) IPF fibroblasts are desensitized to type I collagen matrix-induced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases. PLoS One 9:e94616
Nho, Richard Seonghun; Im, Jintaek; Ho, Yen-Yi et al. (2014) MicroRNA-96 inhibits FoxO3a function in IPF fibroblasts on type I collagen matrix. Am J Physiol Lung Cell Mol Physiol 307:L632-42
Nho, Richard Seonghun; Hergert, Polla (2014) FoxO3a and disease progression. World J Biol Chem 5:346-54